Iconovo AB (publ) (STO:ICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.200
+0.030 (2.56%)
At close: Mar 6, 2026
-63.75%
Market Cap 115.41M
Revenue (ttm) 14.53M
Net Income (ttm) -43.36M
Shares Out 96.17M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 68,619
Average Volume 109,098
Open 1.135
Previous Close 1.170
Day's Range 1.135 - 1.200
52-Week Range 0.906 - 3.980
Beta 0.43
RSI 56.85
Earnings Date Feb 12, 2026

About Iconovo AB

Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for ... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2013
Employees 13
Stock Exchange Nasdaq Stockholm
Ticker Symbol ICO
Full Company Profile

Financial Performance

In 2025, Iconovo AB's revenue was 14.53 million, a decrease of -39.46% compared to the previous year's 24.00 million. Losses were -43.36 million, 5.41% more than in 2024.

Financial Statements

News

There is no news available yet.